Immunocore Holdings ADR earnings missed by $0.16, revenue fell short of estimates
Immunocore Holdings ADR (IMCR) reported Q3 EPS of -$0.28, missing estimates by $0.16, and revenue of $102.22M, below the $113.35M consensus. The stock is down 16.42% over 3 months and 10.75% over 12 months. Analysts revised EPS estimates 8 times negatively in the last 90 days. InvestingPro rates its financial health as 'fair performance'.
How this was made
The 30-second read
Why it matters
The earnings shortfall is likely to drive short-term price weakness, though longer-term catalysts remain unknown.
Market read
Company-specific earnings miss with limited broader market impact.
What to watch
Potential upcoming data readouts or partnership announcements not covered in the article.
Background
Immunocore Holdings ADR (NASDAQ: IMCR) reported its third-quarter results, missing both earnings per share and revenue expectations.
Ticker impact
Q3 earnings missed EPS and revenue estimates, EPS $-0.28 vs -$0.12 estimate, revenue $102.22M vs $113.35M estimate.
downward pressure as market prices in the earnings shortfall
Both EPS and revenue came in below consensus, and the stock has already declined 16% over three months, suggesting investors will react negatively.
Market effects
Biotech sector may see modest pullback as earnings miss highlights execution risk.
Limited to US-listed biotech investors.
Low, confined to company-specific trade.
Counterpoint
The miss may be temporary; pipeline progress could support a rebound.
Key entities
- companyImmunocore Holdings ADR
Biotech firm listed on NASDAQ under ticker IMCR.
